{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:30:07Z","timestamp":1707525007366},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,5]]},"DOI":"10.7759\/cureus.34655","type":"journal-article","created":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T23:44:10Z","timestamp":1675640650000},"source":"Crossref","is-referenced-by-count":0,"title":["Crohn\u2019s Disease-Like Features in a Patient With IgE and Selective IgG1 and IgG3 Deficiency"],"prefix":"10.7759","author":[{"given":"Ioannis","family":"Drygiannakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirini","family":"Theodoraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Tsafaridou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Koutroubakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-019-08756-7","article-title":"The epidemiology and clinical manifestations of autoimmunity in selective IgA deficiency","volume":"58","author":"Odineal DD","year":"2020","unstructured":"Odineal DD, Gershwin ME. The epidemiology and clinical manifestations of autoimmunity in selective IgA deficiency. Clin Rev Allergy Immunol. 2020, 58:107-133. 10.1007\/s12016-019-08756-7","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155223","article-title":"Primary humoral immune deficiencies: overlooked mimickers of chronic immune-mediated gastrointestinal diseases in adults","volume":"21","author":"Malesza IJ","year":"2020","unstructured":"Malesza IJ, Malesza M, Krela-Ka\u017amierczak I, Zieli\u0144ska A, Souto EB, Dobrowolska A, Eder P. Primary humoral immune deficiencies: overlooked mimickers of chronic immune-mediated gastrointestinal diseases in adults. Int J Mol Sci. 2020, 21:10.3390\/ijms21155223","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab124","article-title":"Primary hypogammaglobulinaemia with inflammatory bowel disease-like features: an ECCO CONFER multicentre case series","volume":"16","author":"Albshesh A","year":"2022","unstructured":"Albshesh A, Eder P, Ribaldone DG, et al.. Primary hypogammaglobulinaemia with inflammatory bowel disease-like features: an ECCO CONFER multicentre case series. J Crohns Colitis. 2022, 16:91-97. 10.1093\/ecco-jcc\/jjab124","journal-title":"J Crohns Colitis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa230","article-title":"Serum IgG4 subclass deficiency defines a distinct, commonly encountered, severe inflammatory bowel disease subtype","volume":"27","author":"Koutroumpakis F","year":"2021","unstructured":"Koutroumpakis F, Phillips AE, Yadav D, et al.. Serum IgG4 subclass deficiency defines a distinct, commonly encountered, severe inflammatory bowel disease subtype. Inflamm Bowel Dis. 2021, 27:855-863. 10.1093\/ibd\/izaa230","journal-title":"Inflamm Bowel Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.621337","article-title":"Association of serum immunoglobulins levels with specific disease phenotypes of Crohn's disease: a multicenter analysis in China","volume":"8","author":"Song DJ","year":"2021","unstructured":"Song DJ, Shen J, Chen MH, et al.. Association of serum immunoglobulins levels with specific disease phenotypes of Crohn's disease: a multicenter analysis in China. Front Med (Lausanne). 2021, 8:621337. 10.3389\/fmed.2021.621337","journal-title":"Front Med (Lausanne)"},{"key":"ref6","article-title":"IgG4+ plasma cell infiltration is correlated with the development of inflammatory bowel disease and can be regulated by TLR-4","volume":"11","author":"Chen X","year":"2018","unstructured":"Chen X, Sun W, Lin R, Huang Z, Chen W. IgG4+ plasma cell infiltration is correlated with the development of inflammatory bowel disease and can be regulated by TLR-4. Int J Clin Exp Pathol. 2018, 11:4537-44.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref7","article-title":"The involvement of IgH enhancer HS1.2 in the pathogenesis of Crohn's disease: how the immune system can influence a multifactorial disease","volume":"20","author":"Cianci R","year":"2016","unstructured":"Cianci R, Lolli S, Pagliari D, et al.. The involvement of IgH enhancer HS1.2 in the pathogenesis of Crohn's disease: how the immune system can influence a multifactorial disease. Eur Rev Med Pharmacol Sci. 2016, 20:3618-3627.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1595-3","article-title":"Analysis of the B cell receptor repertoire in six immune-mediated diseases","volume":"574","author":"Bashford-Rogers RJ","year":"2019","unstructured":"Bashford-Rogers RJ, Bergamaschi L, McKinney EF, et al.. Analysis of the B cell receptor repertoire in six immune-mediated diseases. Nature. 2019, 574:122-126. 10.1038\/s41586-019-1595-3","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000456","article-title":"Use of intravenous immunoglobulin for patients with inflammatory bowel disease with contraindications or who are unresponsive to conventional treatments","volume":"21","author":"Merkley SA","year":"2015","unstructured":"Merkley SA, Beaulieu DB, Horst S, Duley C, Annis K, Nohl A, Schwartz DA. Use of intravenous immunoglobulin for patients with inflammatory bowel disease with contraindications or who are unresponsive to conventional treatments. Inflamm Bowel Dis. 2015, 21:1854-1859. 10.1097\/MIB.0000000000000456","journal-title":"Inflamm Bowel Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001116","article-title":"Efficacy and factors associated with treatment response of intravenous immunoglobulin in inpatients with refractory inflammatory bowel diseases","volume":"23","author":"Horton N","year":"2017","unstructured":"Horton N, Kochhar G, Patel K, Lopez R, Shen B. Efficacy and factors associated with treatment response of intravenous immunoglobulin in inpatients with refractory inflammatory bowel diseases. Inflamm Bowel Dis. 2017, 23:1080-1087. 10.1097\/MIB.0000000000001116","journal-title":"Inflamm Bowel Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.04.006","article-title":"Intravenous immunoglobulin for the treatment of Crohn's disease","volume":"12","author":"Rogosnitzky M","year":"2012","unstructured":"Rogosnitzky M, Danks R, Holt D. Intravenous immunoglobulin for the treatment of Crohn's disease. Autoimmun Rev. 2012, 12:275-280. 10.1016\/j.autrev.2012.04.006","journal-title":"Autoimmun Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-963098","article-title":"Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease","volume":"45","author":"Chrissafidou A","year":"2007","unstructured":"Chrissafidou A, Malek M, Musch E. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease. Z Gastroenterol. 2007, 45:605-608. 10.1055\/s-2007-963098","journal-title":"Z Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/136126-crohns-disease-like-features-in-a-patient-with-ige-and-selective-igg1-and-igg3-deficiency","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:37Z","timestamp":1707508177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/136126-crohns-disease-like-features-in-a-patient-with-ige-and-selective-igg1-and-igg3-deficiency"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,5]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.34655","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,5]]}}}